Formulation and clinical evaluation of ultradeformable liposomes in the topical treatment of psoriasis

Clinical Research and Regulatory Affairs

Volumn 25, Issue 1, 2008, Pages 41-52

  Vanaja, K ^a   Rani, R H Shobha ^a   Sacchidananda, S ^b  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b Victoria Hospital   (India)

Author keywords

Methotrexate; PASI; Psoriasis; Ultradeformable Liposomes

Indexed keywords

LIPOSOME; METHOTREXATE;

ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTACT SENSITIZATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; FEMALE; FOLLOW UP; GAS CHROMATOGRAPHY; GEL; HUMAN; MALE; PARTICLE SIZE; PATCH TEST; PATIENT COMPLIANCE; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 40149100806     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330701885116     Document Type: Article

References (26)

1. Andrew LB, Richare AB, Jeffrey WH, Mark PL. Emerging therapeutic targets in psoriasis. Curr Opin Pharmacol. 2004;4:306-310.
2. Linden KG, Gerald DW. Psoriasis: current perspective with an emphasis on treatment. Am J Med. 1999;107:595-605.
3. Mendonca CO, Burden AD. Current concepts in psoriasis and treatment. Pharmacol Ther. 2003;99:133-137.
4. David LM, Douglas GR, Eric AM, Carl DN. Systemic aspects of psoriasis: an integrative model based on intestinal etiology. Integr Med. 1999; 2(2/3):105-113.
5. Frank CS, Alan MM. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol. 2004 Feb;50(2):301-309
6. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm. 2001;215:57-65.
7. Alvarez-Figueroa MJ, Delgado-Charro MB, Blance-Mendez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharm. 2001;212:101-107.
8. Trotta M, Pattarino F, Gasco FR. Influence of counterions on the skin permeation of methotrexate from water-oil microemulsions. Pharm Acta Hel. 1996;71:135-140.
9. Elisie O, Sandip BT, Udupa N, Ravindra K, UmaDevi P. Niosome entrapped B-cyclodextrin methotrexate complex as a drug delivery system. Ind J Pharmacol. 1999;31:279-284.
10. Guangwei L, Won JH. Diffusion studies of methotrexate in carbopol and poloxamer gels. Int J Pharm. 1998;16:1-9.
11. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm. 2004;270:119-115.
12. Schmid MH, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Del Rev. 1996;18:335-342.
13. Cevc G, Gabriele B. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulation drug carriers, Transfersomes? Biochim Biophys Acta. 2003;1614:156-164.
14. Cevc G, Gabriele B. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carrier, Transfersomes? Biochim Biophys Acta. 2001;1514:191-205.
15. Prasad VG, Peter AC, Ram BM. Gas chromatographic determination of residual levels of tert.-butanol from lyophilized liposomal formulations. J Chrom: Biomedical Appli. 1993;620(1):83-88.
16. Lee CR, Dau NV, Krstulovic M. Artefact formation in the determination of residual solvents according to a method of the European Pharmacopeia. Int J Pharm. 2000;195:159-169
17. Coran SA, Giannellini V, Furlanetto S, Alberti MB, Pinzauti S. Improving gas chromatographic determination of residual solvents in pharmaceuticals by the combined use of headspace solid-phase microextraction and isotopic dilution. J Chrom A. 2001;915:209-216.
18. Liu Y and Hua CO. Establishment of a knowledge base for identification of residual solvents in pharmaceuticals. Anal Chim Acta. 2006;575:246-254.
19. Standard Operating Procedures, Clinical Trials 930.00, Repeat Insult Patch Test (RIPT). Based on the method published in Appraisal of the Safety of Chemicals, Drugs and Cosmetics - Association for Food and Drug Officials USA
20. Heidi CM, Alan BF, Elizabeth FS. Patch Testing in an aged population without dermatitis: high prevalence of patch test positivity. Amer J Contact Dermat. 1996;17(3):155-157.
21. Carlin CS, Feldman SR. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-866.
22. Ehrlich A, Booher S, Becerra Y et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol. 2004;50(4):533-540.
23. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of Infliximab monotherapy for plaque-type psoriasis: a randomized trial. The Lancet. 2001;357:1842-1847.
24. Sriram V, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharma Acta Helv. 1995;70:95-111.
25. Vanaja K, Shobha Rani RH. Preformulation study of methotrexate to assess its suitability in transdermal drug delivery. Int J Pharm Excip. 2006; (July-Sept):91.
26. Honeywell-Nguyen LP, Bouwstra JA. The in vitro transport of pergolide from surfactant-based elastic vesicles through human skin: a suggested mechanism of action. J Control Rel. 2003;86:145-156.